Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system

Susan Lösler, Sarah Schlieff, Christiane Kneifel, Eckhard Thiel, Hubert Schrezenmeier, Markus T. Rojewski

► **To cite this version:**

Susan Lösler, Sarah Schlieff, Christiane Kneifel, Eckhard Thiel, Hubert Schrezenmeier, et al.. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system. *Annals of Hematology*, 2009, 88 (11), pp.1047-1058. 10.1007/s00277-009-0736-4 . hal-00535049

HAL Id: hal-00535049

<https://hal.science/hal-00535049>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system

Susan Lösler · Sarah Schließ · Christiane Kneifel ·
Eckhard Thiel · Hubert Schrezenmeier ·
Markus T. Rojewski

Received: 7 August 2008 / Accepted: 9 March 2009 / Published online: 21 March 2009
© Springer-Verlag 2009

Abstract During the last years remission rates of more than 72% for arsenic(III)-oxide (As_2O_3) treatment in relapsed or refractory acute promyelocytic leukemia have been published. As_2O_3 is under clinical investigation for therapy of leukemia and solid tumors. Due to the chemical affinity of arsenic and antimony, we analyzed the potency of antimony (III)-oxide (Sb_2O_3) to exert As_2O_3 -like effects. Based on the same molar concentrations, lower efficacy in apoptosis induction and caspase-independent decrease of mitochondri-

al membrane potential was observed for Sb_2O_3 . No difference in sensitivity to As_2O_3 or Sb_2O_3 was detected in CEM cells when compared to their multiple drug resistant derivatives. Apoptosis was induced by combining sub-apoptotic concentrations of Sb_2O_3 or As_2O_3 with sub-apoptotic concentrations of DL-buthionine-[S,R]-sulfoximine (BSO). Other modulators of the cellular redox system showed this effect to a lower extent and enhancement was not consistent for the different cell lines tested. Caspase inhibitors protected cell lines from Sb_2O_3 - and As_2O_3 -induced apoptosis. When BSO was added, the inhibitors lost their protective ability. The ability of modulators of the cellular redox system in clinically applicable concentrations to enhance the apoptotic effects of the two oxides in a synergistic way may be helpful to reduce their toxicity by optimizing their dose.

S. Lösler · S. Schließ · C. Kneifel · E. Thiel
Medizinische Klinik III (Hämatologie, Onkologie und
Transfusionsmedizin), Charité Universitätsmedizin Berlin,
Campus Benjamin Franklin, Hindenburgdamm 30,
12203 Berlin, Germany

C. Kneifel
Augenklinik, Charité Universitätsmedizin Berlin,
Campus Benjamin Franklin, Hindenburgdamm 30,
12203 Berlin, Germany

H. Schrezenmeier · M. T. Rojewski (✉)
Institut für Transfusionsmedizin, Universität Ulm,
Helmholtzstraße 10,
89081 Ulm, Germany
e-mail: markus.rojewski@uni-ulm.de

H. Schrezenmeier · M. T. Rojewski
Institut für klinische Transfusionsmedizin und Immunogenetik,
DRK Blutspendedienst Baden-Württemberg—Hessen,
Helmholtzstraße 10,
89081 Ulm, Germany

Keywords Apoptosis · Arsenic · Antimony ·
Buthionine sulfoximine · Glutathione · Redox system

Introduction

During the last 10 years, several groups demonstrated remission of more than 72% for arsenic(III)-oxide (As_2O_3) treatment in relapsed or refractory acute promyelocytic leukemia (APL), as presented in various reviews [1–5]. As_2O_3 was established as a potent alternative in therapy of all-*trans* retinoic acid (ATRA)-resistant APL and shows, like Sb_2O_3 , similar cellular effects to ATRA in APL: localization of the t(15;17) specific PML-RAR α -fusion protein in

nuclear bodies and degradation of the fusion protein [6–9] and induction of differentiation and apoptosis [10–14]. Lately, we showed that induction of apoptosis by As_2O_3 in 22 myeloid and non-myeloid malignant cell lines of different sensitivity for cytostatic drugs, is based on breakdown of the mitochondrial membrane potential (Ψ_m) and therefore the redox system of the cell is one of the primary targets of As_2O_3 . Activation of caspases is a downstream effect occurring after the breakdown of Ψ_m [15–17] and release of radical oxygen species (ROS) [18–21].

Both antimony and arsenic are members of the Vth group of the table of elements and share common chemical characteristics. Based on the affinity of As_2O_3 and Sb_2O_3 we analyzed whether Sb_2O_3 shows similar efficacy and identical mechanisms of action by investigation of the effects of Sb_2O_3 on representative myeloid cell lines of different sensitivity groups for As_2O_3 as classified in our previous report [22]. Given the increasing clinical use of As_2O_3 , we were, in particular, interested in combinations that might be transferable to clinical application. Inhibitors of the cellular glutathione system were used to modulate the efficacy of As_2O_3 and Sb_2O_3 to induce apoptosis. The modulators analyzed in this report include the γ -glutamylcystein synthetase inhibitor DL-buthionine-[S,R]-sulfoximine (BSO),

the glutathione peroxidase (GPx) inhibitor mercaptosuccinic acid (MS), as well as sodium ascorbate (NaAsc), sodium salicylate (NaSal), and 3-amino-1,2,4-azole (AT). Ascorbate was shown to decrease in glutathione-deficient rats and ascorbate spares glutathione and protects [23], NaSal potentiates the toxicity of BSO in the E47 cells [24] and AT inhibits catalase in the presence of H_2O_2 and inhibits cyclizations leading to β -carotene and Φ -carotene accumulates. As far as data were achievable and tolerable concentrations of the different substances in vivo were available (BSO, NaAsc, NaSal), we have chosen concentrations within this range. For As_2O_3 and Sb_2O_3 we have chosen incubation times and concentrations as we previously published for As_2O_3 [15, 17, 22]. The As_2O_3 concentrations are in the range of peak values of clinically achievable As_2O_3 plasma levels as shown by pharmacokinetic analysis [10].

Materials and methods

Cell culture

Cell lines CCRF-CEM, HL-60, K-562, and LOUCY were purchased from The German Collection of Microorganisms

Fig. 1 Sb_2O_3 - and As_2O_3 -induced apoptosis in myeloid and lymphatic cell lines. Cell lines LOUCY, CCRF-CEM, HL-60, and K-562 were treated with PBS (black circle), 1 μM (white square) or 5 μM (black square) Sb_2O_3 or 1 μM (white triangle) or 5 μM (black

triangle) As_2O_3 for 35 days. The percentage of 7-AAD-positive cells was determined before incubation and after 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, and 35 days by flow cytometry

and Cell Cultures (DSMZ, Braunschweig, Germany), CEM/C1, CEM/C2, HL-60/MX1, and HL-60/MX2 from the American Type Culture Collection (Manassas, USA). The doxorubicin resistant cell lines K-562(0.02) and K-562(0.1) were described previously [22].

Induction of apoptosis with antimony(III)-trioxide (Sb_2O_3), arsenic(III)-trioxide (As_2O_3) and cytostatic drugs

Apoptosis was induced with freshly prepared aqueous stock solutions of 1 mM Sb_2O_3 (Fluka, Buchs, Switzerland) or 1 mM As_2O_3 (SIGMA, Deisenhofen, Germany) in PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$ (Invitrogen/GIBCO Life Technologies, Karlsruhe, Germany). Due to its low solubility in H_2O , Sb_2O_3 had to be dissolved in HCl_{conc} before dilution in PBS. The pH of Sb_2O_3 -solutions was determined for each assay and a separate control with the corresponding amount of PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$ and the HCl_{conc} -adjusted adequate pH was used for each experimental approach. Stock solutions of 10 mM of (*S*)-(+)-camptothecin (SIGMA, Deisenhofen, Germany) in dimethyl sulfoxide (Sigma, Deisenhofen, Germany), 10 mM mitoxantrone hydrochloride (SIGMA, Deisenhofen, Germany) and 1 mg/mL doxorubicin hydrochloride (SIGMA, Deisenhofen, Germany) in 70 % ethanol (Carl ROTH GmbH, Karlsruhe, Germany) were used for further dilutions. Cells were seeded according to their optimal growth condition indicated by the provider.

Annexin V-FITC- and 7-AAD-staining

As described previously [22], the percentage of apoptotic cells was determined by two-color flow cytometry using an Annexin V-FITC (BD Pharmingen, Heidelberg, Germany) and 7-amino-actinomycin D (7-AAD) system (Sigma, Deisenhofen, Germany). Whenever possible, fluorescence data of 50.000 cells was acquired using fluorescence channels FL-1 and FL-3 of a FACScan (Becton Dickinson, Heidelberg, Germany). All experiments presented were performed three times, with the exception of those presented in Figs. 1, 5, and 6. In general, flow cytometry analysis was performed until the percentage of apoptotic cells was higher than 90% and acquisition of data was preformed for two further time points.

MitoTrackerRed CMXRos staining

MitoTrackerRed CMXRos (Molecular Probes, Leiden, The Netherlands) is a fluorescent dye that is enriched in mitochondria in a membrane potential dependent manner and reacts with mitochondrial proteins [25, 26]. Therefore, MitoTrackerRed CMXRos, can be used to detect cells with a loss of Ψ_m [27, 28]. The CMX group binds to SH groups

of mitochondrial proteins and is retained in living cells, while unbound dye can be washed out of the cells. Staining was performed as described in a previous report in 1 mL cell suspension (ca. 5×10^5 to 1×10^6 cells) in the presence of 200 nM MitoTrackerRed CMXRos. After 45 min, cells were washed twice in PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$ and the change of fluorescence intensity was measured by flow cytometry [15]. In order to compare the percentage of

Fig. 2 Sb_2O_3 -induced apoptosis occurs in camptothecin-resistant CCRF-CEM derivatives CEM/C1 and CEM/C2. Incubation of the cell lines CCRF-CEM, CEM/C1 and CEM/C2 was performed with PBS (black circle), 1 μM (white square) and 5 μM (white square) Sb_2O_3 as well as with 50 nM (gray rhomb), 150 nM (white rhomb) and 500 nM (black rhomb) camptothecin for 22 days. The percentage of 7-AAD-positive cells was determined before incubation and after 2, 4, 7, 10, 14, and 22 days

apoptotic cells (as measured by 7-AAD and Annexin V positivity in flow cytometry) and the percentage of cells with reduced Ψ_m , the following presentation was chosen for MitoTrackerRed CMXRos staining: the fluorescence intensity of untreated control cells was set to approximately 10^2 as described by the manufacturer. The percentage of cells with reduced staining pattern for MitoTrackerRed CMXRos (compared to the untreated controls) were referred as MitoTrackerRed CMXRos-negative. The percentage of the population with reduced fluorescence intensity (negative population) is shown in the diagrams, as these cells did not accumulate the dye in their mitochondria due to their reduced Ψ_m .

Incubation with caspase inhibitors

Cells were washed in PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$ and resuspended at a density of $2\text{--}4 \times 10^5$ cells/mL in serum free QBSF51® medium (Sigma, Deisenhofen, Germany). Caspase inhibitors Boc-D(OMe)-Fmk, Z-VAD-FMK and

Z-D(OMe)-E(OMe)-VD(OMe)-Fmk (all from ALEXIS Biochemicals, Grünberg, Germany) were dissolved in DMSO and used in a final concentration of 50 μM . CCRF-CEM and HL-60 cells were incubated (37°C , 6% CO_2 , 98% humidity) in the presence of the inhibitors for 1 h prior to cultivation with Sb_2O_3 or As_2O_3 .

Incubation with modulators of the cellular GSH-redox system

Fresh stock solutions of 100 mM DL-buthionine-[S,R]-sulfoximine (Sigma, Deisenhofen, Germany), 500 mM sodium salicylate (Sigma, Deisenhofen, Germany), 500 mM sodium ascorbate (Sigma, Deisenhofen, Germany), 100 mM mercaptosuccinic acid (Sigma, Deisenhofen, Germany) and 20 mM 3-amino-1,2,4-azole (Sigma, Deisenhofen, Germany) were prepared in PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$ for each assay. All modulators of GSH were added together with PBS or the inducers of apoptosis (Sb_2O_3 and As_2O_3), when indicated.

Fig. 3 Modulation of Sb_2O_3 -induced apoptosis by NaSal, NaAsc, BSO, MS and AT in cell line LOUCY. Cell line LOUCY was incubated either with **a** PBS, **b** 1 μM As_2O_3 , **c** 1 μM Sb_2O_3 , or **d** 5 μM Sb_2O_3 alone (black circle) or in combination with 250 μM NaSal (white square), 250 μM NaAsc (black square), 100 μM BSO (black rhomb), 100 μM MS (white triangle) or 20 mM AT (black

triangle) for 7 days. The percentage of cells positive for 7-AAD was determined before incubation and after 1, 2, 4, and 7 days. *The control shown in **a**, **b**, **c**, and **d** represents the corresponding assays with PBS or the inducers of apoptosis alone (Sb_2O_3 or As_2O_3) but without the modulators of Ψ_m .

Results

Sb₂O₃ and As₂O₃ induce apoptosis in lymphohematopoietic cell lines

As we demonstrated in a recent report [22], concentrations of As₂O₃ that are achievable in the plasma of As₂O₃-treated APL-patients induced apoptosis in a variety of different lymphohematopoietic cell lines. We introduced a classification system according to the sensitivity of cell lines towards As₂O₃-induced apoptosis. To investigate the apoptosis-inducing potential of Sb₂O₃, we have chosen representative cell lines from the different sensitivity groups and incubated the cell lines LOUCY, CCRF-CEM, HL-60 and K-562 with either PBS, 1 μ M As₂O₃, 5 μ M As₂O₃, 1 μ M Sb₂O₃ or 5 μ M Sb₂O₃. Apoptosis was measured by staining with 7-AAD (Fig. 1) and Annexin V-FITC (data not shown). Based on experience with As₂O₃ that induced apoptosis in vivo and in some cell lines only after prolonged incubation [10, 22, 29, 30], we determined the

percentage of apoptotic cells before incubation and after 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, and 35 days by flow cytometry.

Low concentration (1 μ M) As₂O₃ induced apoptosis in LOUCY and CCRF-CEM-cells, whereas 1 μ M Sb₂O₃ was not effective in any of the analyzed cell lines. When incubated with 5 μ M As₂O₃, apoptosis occurred in all four cell lines. Only the MDR-1 positive cell lines K-562 was resistant to the high concentration of Sb₂O₃ (5 μ M). We observed a high correlation between both methods used for the detection of apoptotic cells, Annexin V-FITC- and 7-AAD-staining: correlation coefficients were 0.999 for LOUCY, 0.994 for CCRF-CEM, 0.934 for HL-60, 0.815 for K-562, and 0.940 over all, respectively.

Sb₂O₃ and As₂O₃ induce apoptosis in cytostatic-resistant cell lines of the lymphohematopoietic system

Sensitivity to induction of apoptosis by As₂O₃ did not differ between CCRF-CEM and the less cytostatic-sensitive deriv-

Fig. 4 Enhancement of Sb₂O₃-induced apoptosis by NaSal, NaAsc, BSO, MS, and AT in cell line CCRF-CEM. Cell line CCRF-CEM was incubated either with **a** PBS, **b** 1 μ M As₂O₃, **c** 1 μ M Sb₂O₃, or **d** 5 μ M Sb₂O₃ alone (black circle) or in combination with 500 μ M NaSal (white square), 500 μ M NaAsc (black square), 100 μ M BSO (black rhomb), 100 μ M MS (white triangle) or 20 mM AT (black

triangle) for 7 days. The percentage of cells positive for 7-AAD was determined before incubation and after 1, 2, 4, and 7 days. *The control shown in (a), (b), (c), and (d) represents the corresponding assays with PBS or the inducers of apoptosis alone (Sb₂O₃ or As₂O₃) but without the modulators of Ψ_m

atives CEM/C1 and CEM/C2 [22]. This prompted the question whether also Sb_2O_3 can induce apoptosis in these two cell lines with multiple drug resistance [31, 32]. Figure 2 summarizes data on Sb_2O_3 - and camptothecin-treatment of CCRF-CEM, CEM/C1, and CEM/C2 cells which were incubated with Sb_2O_3 (1 μM or 5 μM) or camptothecin (50–500 nM; positive control for apoptosis induction) for up to 22 days. Based on equimolar concentrations, As_2O_3 was generally more potent as compared to Sb_2O_3 .

CCRF-CEM cells were insensitive to 1 μM Sb_2O_3 but sensitive to 5 μM Sb_2O_3 and all concentrations of camptothecin. CEM/C1 cells showed less sensitivity to 50 and 150 nM camptothecin, however, were still sensitive to 5 μM Sb_2O_3 . Cell line CEM/C2 that was resistant to camptothecin up to 500 nM still retained sensitivity to 5 μM Sb_2O_3 . In contrast to As_2O_3 [22], no prolonged incubation time was necessary to induce apoptosis with increasing resistance to camptothecin for Sb_2O_3 . Again, there was a high correlation between both methods used for the detection of apoptotic cells, Annexin V-FITC- and 7-AAD-staining: correlation coefficients were 0.973 for CCRF-CEM, 0.974

for CEM/C1, 0.961 for CEM/C2, and 0.978 over all, respectively.

The HL-60 mitoxantrone resistant derivatives HL-60/MX1 and HL-60/MX2 and the K-562 doxorubicin resistant derivatives K-562(0.02) and K-562(0.1) were insensitive to 1 μM Sb_2O_3 and 5 μM Sb_2O_3 (data not shown). As previously shown, these derivatives show reduced sensitivity to 1 μM As_2O_3 and 5 μM As_2O_3 as compared to their corresponding parental cell lines [22].

Increased sensitivity towards Sb_2O_3 - and As_2O_3 - induced apoptosis by modulators of the cellular GSH-system

We addressed the potential role of the glutathione redox system for Sb_2O_3 - and As_2O_3 -mediated apoptosis: cell lines LOUCY (Fig. 3), CCRF-CEM (Fig. 4), HL-60 (Fig. 5) and K-562 (Fig. 6) were treated with different substances known to influence Ψ_m or to modulate or inhibit the synthesis of glutathione.

Therefore, we incubated the indicated cell lines for 7 days (LOUCY) or 14 days (CCRF-CEM, HL-60, K-562) with

Fig. 5 Enhancement of Sb_2O_3 -induced apoptosis by NaSal, NaAsc, BSO, MS, and AT in cell line HL-60. Cell line HL-60 was incubated either with **a** PBS, **b** 1 μM As_2O_3 , **c** 1 μM Sb_2O_3 or **d** 5 μM Sb_2O_3 alone (black circle) or in combination with 1 mM NaSal (white square), 1 mM NaAsc (black square), 100 μM BSO (black rhomb), 100 μM MS (white triangle) or 20 mM AT (black triangle) for

14 days. The percentage of cells positive for 7-AAD was determined before incubation and after 1, 2, 4, 7, 10, and 14 days. *The control shown in **a**, **b**, **c**, and **d** represents the corresponding assays with PBS or the inducers of apoptosis alone (Sb_2O_3 or As_2O_3) but without the modulators of Ψ_m

Fig. 6 Enhancement of Sb_2O_3 -induced apoptosis by NaSal, NaAsc, BSO, MS and AT in cell line K-562. Cell line K-562 was incubated either with **a** PBS, **b** $1 \mu\text{M As}_2\text{O}_3$, **c** $1 \mu\text{M Sb}_2\text{O}_3$ or **d** $5 \mu\text{M Sb}_2\text{O}_3$ alone (black circle) or in combination with $500 \mu\text{M NaSal}$ (white square), $500 \mu\text{M NaAsc}$ (black square), $100 \mu\text{M BSO}$ (black rhomb), $100 \mu\text{M MS}$ (white triangle) or 20 mM AT (black triangle) for

14 days. The percentage of cells positive for 7-AAD was determined before incubation and after 1, 2, 4, 7, 10, and 14 days. *The control shown in **a**, **b**, **c**, and **d** represents the corresponding assays with PBS or the inducers of apoptosis alone (Sb_2O_3 or As_2O_3) but without the modulators of Ψ_m

either PBS (Figs. 3a, 4a, 5a, 6a), $1 \mu\text{M As}_2\text{O}_3$ (Figs. 3b, 4b, 5b, 6b), $1 \mu\text{M Sb}_2\text{O}_3$ (Figs. 3c, 4c, 5c, 6c) or $5 \mu\text{M Sb}_2\text{O}_3$ (Figs. 3d, 4d, 5d, 6d) alone or together with sodium salicylate (NaSal, $500 \mu\text{M}$ for LOUCY, CCRF-CEM and K-562, 1 mM for HL-60), sodium ascorbate (NaAsc, $500 \mu\text{M}$ for LOUCY, CCRF-CEM and K-562, 1 mM for HL-60), DL-buthionine-[S, R]-sulfoximine (BSO, $100 \mu\text{M}$ for all cell lines), mercaptosuccinic acid (MS, $100 \mu\text{M}$ for all cell lines) or 3-amino-1,2,4-azole (AT, 20 mM for all cell lines). The percentages of 7-AAD- and Annexin V-FITC (data not shown)-positive cells were determined before incubation and after 1, 2, 4, 7, 10, and 14 days. None of the modulators or inhibitors alone triggered apoptosis, with the exception of MS for cell lines LOUCY and HL-60 and NaAsc for cell line K-562, where an increase of the apoptotic population could be observed.

In general, strong enhancement of the two oxides Sb_2O_3 ($1 \mu\text{M}$ and $5 \mu\text{M}$) and As_2O_3 ($1 \mu\text{M}$) by the inhibitor of the γ -glutamylcystein synthetase BSO could be seen. Even when Sb_2O_3 or As_2O_3 were used in concentrations that were not or only weak effective by themselves ($1 \mu\text{M Sb}_2\text{O}_3$ for LOUCY, CCRF-CEM and HL-60; $5 \mu\text{M Sb}_2\text{O}_3$ for K-562;

$1 \mu\text{M As}_2\text{O}_3$ for CCRF-CEM and HL-60, $5 \mu\text{M As}_2\text{O}_3$ for K-562), an increase up to 100% of apoptotic cells was observed when $100 \mu\text{M BSO}$ were added to the assay. This phenomenon was consistently seen with all analyzed cell lines and was in particular remarkable with the cell line K-562 that was insensitive for Sb_2O_3 -concentrations even higher than $5 \mu\text{M}$ (up to $10 \mu\text{M}$, data not shown). Other modulators were less effective and did not demonstrate consistent synergistic results in all cell lines: NaAsc (250 or $500 \mu\text{M}$) also induced slight increase in CCRF-CEM and K-562. In CCRF-CEM a synergistic effect was seen with $500 \mu\text{M NaAsc}$ and $1 \mu\text{M Sb}_2\text{O}_3$ which both were insensitive as single agents. Prolonged incubation with MS ($100 \mu\text{M}$) did enhance As_2O_3 - and Sb_2O_3 -induced apoptosis in HL-60 and K-562, but not in CCRF-CEM. Both AT and NaSal did not show consistent effects with the inducers of apoptosis in the different cell lines.

A high correlation of Annexin V-FITC and 7-AAD-staining could be demonstrated for all assays: correlation coefficients were 0.993 for LOUCY, 0.956 for CCRF-CEM, 0.913 for HL-60, 0.885 for K-562, respectively.

Effects of caspase inhibitors on Sb_2O_3 - and As_2O_3 -induced apoptosis and breakdown of Ψ_m in the T-cell leukemia cell line CCRF-CEM

In order to study the role of caspases and Ψ_m on Sb_2O_3 - and As_2O_3 -induced effects, we pre-treated the T-cell line CCRF-CEM with various caspase inhibitors (Fig. 7).

Pre-incubation was performed with three different caspase inhibitors for 1 h prior to (apoptosis) induction with Sb_2O_3 (5 and 10 μM) or As_2O_3 (5 μM): Boc-D(OMe)-Fmk and Z-VAD-Fmk are potent pan-caspase inhibitors, whereas Z-D(OMe)-E(OMe)-VD(OMe)-Fmk preferentially inhibits Caspase-3 but also to lower extend Caspase-6, Caspase-7, Caspase-8, and Caspase-10. The percentage of Annexin V-positive and MitoTrackerRed CMXRos-negative cells was determined after 24 h of apoptosis induction. The inhibitors alone showed no increase in the percentage of apoptotic cells (as measured by Annexin V-FITC-staining; Fig. 7) or any change in Ψ_m (as measured by MitoTrackerRed CMXRos staining; Fig. 7). We did not observe effects of caspase inhibitors on the percentage of MitoTrackerRed CMXRos-negative cells, whereas the percentage of cells stained positive for Annexin V-FITC declined. The inhibitory effect of the caspase inhibitors on Annexin V-FITC-binding was most prominent after pre-incubation for 1 h but not detectable with concomitant addition together with Sb_2O_3 or As_2O_3 (data not shown).

Modulation of the intracellular GSH-level by BSO affects the anti-apoptotic potential of caspase inhibitor Z-VAD-Fmk in cell line HL-60

Pre-incubation of HL-60 cells was performed with the pan-caspase inhibitor Z-VAD-Fmk for 1 h prior to treatment with Sb_2O_3 (10 and 20 μM) or As_2O_3 (5 and 10 μM) alone or in combination with 30 μM or 100 μM BSO. In order to induce apoptosis within 48 h in HL-60 cells, higher concentrations of As_2O_3 and Sb_2O_3 were chosen. The percentage of Annexin V-positive and MitoTrackerRed CMXRos-negative cells was determined after 48 h of apoptosis induction (Fig. 8). The inhibitor Z-VAD-Fmk alone showed no increase in the percentage of apoptotic cells or in Ψ_m , whereas reduction of the decrease in Ψ_m of BSO-treated non-apoptotic HL-60 could be detected. When Z-VAD-Fmk-pre-incubated cells were treated with 10 μM As_2O_3 , a reduction of the percentage of MitoTrackerRed CMXRos-negative cells could be observed, compared to cells treated with As_2O_3 alone. This effect was not detectable for Sb_2O_3 , as Sb_2O_3 -induced apoptosis occurred in a low percentage (<20%) of cells under these conditions. When HL-60 cells were pre-treated with the caspase inhibitor, the percentage of apoptotic cells declined for 10 μM As_2O_3 or 20 μM Sb_2O_3 . However, when either 30 μM or 100 μM BSO was added, Z-VAD-Fmk lost its potency to reduce both apoptosis and decrease of Ψ_m . Moreover, even in cells pre-incubated with

Fig. 7 Sb_2O_3 - and As_2O_3 -induced effects on Ψ_m cannot be blocked by caspase inhibitors in CCRF-CEM cells despite the percentage of apoptotic cells measured by Annexin V-FITC binding is reduced. After 1 h pre-incubation with the pan-caspase inhibitor Boc-D(OMe)-Fmk or the multiple-caspase inhibitors Z-VAD-Fmk or Z-D(OMe)-E

(OMe)-VD(OMe)-Fmk, CCRF-CEM cells were co-incubated with 5 μM or 10 μM Sb_2O_3 or 5 μM As_2O_3 for 24 h. The percentage of cells positive for Annexin V-FITC (white bars) and negative for MitoTrackerRed CMXRos (gray bars) was measured by flow cytometry

Fig. 8 Inhibition of Sb_2O_3 - and As_2O_3 -induced loss of Ψ_m and reduction of the percentage of apoptotic cells (measured by Annexin V-FITC binding) by caspase inhibitors is dependent from GSH-modulation in HL-60 cells. After 1 h pre-incubation with the pan-caspase inhibitor Z-VAD-Fmk, HL-60 cells were co-incubated with 30 μM or 100 μM BSO and PBS, 10 μM Sb_2O_3 , 20 μM Sb_2O_3 , 5 μM As_2O_3 or 10 μM As_2O_3 for 48 h. The percentage of cells positive for Annexin V-FITC (white bars) and negative for MitoTrackerRed CMXRos (gray bars) was determined by flow cytometry

the pan-caspase inhibitor Z-VAD-Fmk, both 30 μM and 100 μM BSO exerted the synergistic effect already described in Fig. 5 for lower As_2O_3 and Sb_2O_3 concentrations but longer incubation times.

Discussion

We were interested in magnifying the efficacy of As_2O_3 using substances that might be transferable to clinical application because the clinical applications of As_2O_3 gain in importance not only for therapy of relapsed and refractory APL [29, 30, 33–47], but also for treatment of multiple myeloma [48–50], myelodysplastic syndromes [51–53], and renal cancer [54]. Recently, two reports described apoptosis induction, caspase activation and ROS production by very high concentrations (up to 40 μM) of potassium antimonyl tartrate in lymphoid tumor cell lines [55] and growth inhibition and induction of apoptosis and reactive oxygen species [56]. Due to the chemical affinity of Sb_2O_3 and As_2O_3 , we expected the same mechanism of apoptosis induction for the two substances. We observed Sb_2O_3 -induced apoptosis in different myeloid and lymphatic cell lines (CCRF-CEM, HL-60, K-562), among them cell lines with reduced sensitivity to cytostatic agents (LOUCY, CEM/C1, CEM/C2). We were able to block Sb_2O_3 -induced

apoptosis by caspase inhibitors and, as presented previously for As_2O_3 [15], caspase-independent decrease of Ψ_m . We therefore postulate a common mechanism for Sb_2O_3 and As_2O_3 mediated apoptosis. However, based on the same molar concentrations, lower efficacy in apoptosis induction was observed for Sb_2O_3 than for As_2O_3 .

Our special focus was set on substances that influence the glutathione redox state of the cell. Decrease of Ψ_m was shown to play a crucial role in As_2O_3 therapy-relevant effects [15, 17]. These effects are most probably based on inhibition of enzymes of the intracellular glutathione redox system, such as glutathione peroxidase GPx [57, 58], glutathione reductase GR and glutathione-S-transferase [58], resulting in an increase of ROS. In addition, a direct targeting of the mitochondrial permeability transition pore [59] was discussed as a possible mechanism. In this work, we were able to show enhancement of As_2O_3 and Sb_2O_3 effects by BSO, NaSal, NaAsc, MS and AT to different extents. As far as data on achievable and tolerable concentrations in vivo were available (BSO, NaSal, NaAsc), we have chosen concentrations within this range. Mainly BSO, an inhibitor of the rate limiting enzyme in glutathione (GSH)-synthesis γ -glutamylcystein synthetase [57, 60] proved to be a potent enhancer of As_2O_3 and Sb_2O_3 . Our results obtained with As_2O_3 are in accordance with those from Dai et al. [61] and Zhu et al. [14], who

proved that BSO enhances apoptosis induction and decrease of Ψ_m in NB-4 and malignant lymphocytic cell lines and primary cultures of lymphocytic leukemia and lymphoma cells. Sub-apoptotic concentrations of As_2O_3 and Sb_2O_3 can be intensified by sub-apoptotic concentrations of BSO even in cell lines with reduced sensitivity for conventional cytostatic drugs. Repression of As_2O_3 - and Sb_2O_3 -induced apoptosis by the caspase inhibitor Z-VAD-Fmk can be overcome by co-treatment of BSO. Therefore, this substance may be useful in treatment of malignancies in case of reduced sensitivity for apoptosis induction by agents affecting Ψ_m or caspase activation.

Other known modulators of the glutathione redox system showed these effects to a lower extent and enhancement was not as consistent as with BSO, regarding the different cell lines treated. Nevertheless, the efficacy of enhancing As_2O_3 - and Sb_2O_3 -induced decrease of Ψ_m not only by BSO but also to lower extent by MS and ascorbic acid could be shown in this report. Ascorbic acid [61] and MS [62] also were shown to enhance the effects of As_2O_3 on mitochondria. In contradiction to our results, ascorbic acid was shown to protect from As_2O_3 -induced toxicity [63]. However, evidence exists that ascorbic acid, widely praised as an antioxidant [64], can act as an oxidizing agent in the presence of ROS-inducing substances [65, 66]. Recently, promising results of a phase I/II combined trial of As_2O_3 and ascorbic acid were presented [47, 67–69].

Overall, we were able to decipher the mechanism of Sb_2O_3 -induced apoptosis and show that the basic mechanisms involved are the same as described for As_2O_3 . We also have blocked three different enzymes involved in oxidative stress detoxification (catalase, γ -glutamylcystein synthetase, glutathione peroxidase) and shown that only BSO, the inhibitor of the γ -glutamylcystein synthetase, was highly synergistic with sub-apoptotic concentrations of As_2O_3 or Sb_2O_3 . The ability of specific drugs in clinically applicable concentrations to enhance the apoptotic effects of the two oxides in a synergistic way may be helpful in reduction of their toxicity by the optimization of their doses. Moreover, further experiments may show how far our results on synergistic actions may be transferable for other combinations of drugs affecting the glutathione redox system and conventional cytostatic agents.

References

1. Rojewski MT, Korper S, Schrezenmeier H (2004) Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. *Leuk Lymphoma* 45:2387–2401. doi:10.1080/10428190412331272686
2. Amadori S, Fenaux P, Ludwig H, O'Dwyer M, Sanz M (2005) Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. *Curr Med Res Opin* 21:403–411. doi:10.1185/030079904X20349
3. Bonati A, Rizzoli V, Lunghi P (2006) Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. *Curr Pharm Biotechnol* 7:397–405. doi:10.2174/138920106779116829
4. Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. *J Clin Oncol* 23:2396–2410. doi:10.1200/JCO.2005.10.217
5. Kalmadi SR, Hussein MA (2006) The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. *Acta Haematol* 116:1–7. doi:10.1159/000092341
6. Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. *EMBO J* 17:61–70. doi:10.1093/emboj/17.1.61
7. Muller S, Miller WH Jr, Dejean A (1998) Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. *Blood* 92:4308–4316
8. Sternsdorf T, Puccetti E, Jensen K et al (1999) PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. *Mol Cell Biol* 19:5170–5178
9. Lallemand-Breitenbach V, Zhu J, Puvion F et al (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11 S proteasome recruitment, and As_2O_3 -induced PML or PML/retinoic acid receptor alpha degradation. *J Exp Med* 193:1361–1371. doi:10.1084/jem.193.12.1361
10. Chen GQ, Shi XG, Tang W et al (1997) Use of arsenic trioxide (As_2O_3) in the treatment of acute promyelocytic leukemia (APL): I. As_2O_3 exerts dose-dependent dual effects on APL cells. *Blood* 89:3345–3353
11. Bruserud O, Gjertsen BT, Huang T (2000) Induction of differentiation and apoptosis—a possible strategy in the treatment of adult acute myelogenous leukemia. *Oncologist* 5:454–462. doi:10.1634/theoncologist.5-6-454
12. Calleja EM, Warrell RP (2000) Differentiating agents in pediatric malignancies: all-*trans*-retinoic acid and arsenic in acute promyelocytic leukemia. *Curr Oncol Rep* 2:519–523. doi:10.1007/s11912-000-0105-x
13. Huff J, Waalkes M, Nyska A, Chan P (1999) Re: apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. *J Natl Cancer Inst* 91:1690–1691. doi:10.1093/jnci/91.19.1690 letter
14. Zhu XH, Shen YL, Jing YK et al (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. *J Natl Cancer Inst* 91:772–778. doi:10.1093/jnci/91.9.772
15. Rojewski MT, Körper S, Thiel E, Schrezenmeier H (2004) Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines. *Chem Res Toxicol* 17:119–128. doi:10.1021/tx034104+
16. Nolte F, Friedrich O, Rojewski M, Fink RH, Schrezenmeier H, Körper S (2004) Depolarisation of the plasma membrane in the arsenic trioxide (As_2O_3)- and anti-CD95-induced apoptosis in myeloid cells. *FEBS Lett* 578:85–89. doi:10.1016/j.febslet.2004.10.075
17. Körper S, Nolte F, Thiel E, Schrezenmeier H, Rojewski MT (2004) The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines. *Br J Haematol* 124:186–189. doi:10.1046/j.1365-2141.2003.04742.x
18. Tsai S, Hsieh M, Chen L, Liang Y, Lin J, Lin S (2001) Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. *Toxicol Lett* 123:11–19. doi:10.1016/S0378-4274(01)00373-3

19. Yi J, Gao F, Shi G, Li H, Shi X, Tang X (2002) Apoptosis susceptibility of tumor cells to arsenic trioxide and the inherent cellular level of reactive oxygen species. *Chin Med J (Engl)* 115:603–606
20. Nakagawa Y, Akao Y, Morikawa H et al (2002) Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. *Life Sci* 70:2253–2269. doi:10.1016/S0024-3205(01)01545-4
21. Choi YJ, Park JW, Suh SI et al (2002) Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. *Int J Oncol* 21:603–610
22. Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H (2002) Dual effects of arsenic trioxide (As_2O_3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. *Br J Haematol* 116:555–563. doi:10.1046/j.0007-1048.2001.03298.x
23. Martensson J, Meister A (1991) Glutathione deficiency decreases tissue ascorbate levels in newborn rats: ascorbate spares glutathione and protects. *Proc Natl Acad Sci USA* 88:4656–4660. doi:10.1073/pnas.88.11.4656
24. Wu D, Cederbaum A (2004) Glutathione depletion in CYP2E1-expressing liver cells induces toxicity due to the activation of p38 mitogen-activated protein kinase and reduction of nuclear factor-kappaB DNA binding activity. *Mol Pharmacol* 66:749–760. doi:10.1124/mol.104.002048
25. Macho A, Decaudin D, Castedo M et al (1996) Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. *Cytometry* 25:333–340. doi:10.1002/(SICI) 1097-0320(19961201) 25:4<333::AID-CYTO4>3.0.CO;2-E
26. Gilmore K, Wilson M (1999) The use of chloromethyl-X-rosamine (Mitotracker red) to measure loss of mitochondrial membrane potential in apoptotic cells is incompatible with cell fixation. *Cytometry* 36:355–358. doi:10.1002/(SICI) 1097-0320(19990801) 36:4<355::AID-CYTO11>3.0.CO;2-9
27. Leira F, Vieites JM, Vieytes MR, Botana LM (2001) Apoptotic events induced by the phosphatase inhibitor okadaic acid in normal human lung fibroblasts. *Toxicol In Vitro* 15:199–208. doi:10.1016/S0887-2333(01) 00013-3
28. Buckman JF, Hernandez H, Kress GJ, Votyakova TV, Pal S, Reynolds IJ (2001) MitoTracker labeling in primary neuronal and astrocytic cultures: influence of mitochondrial membrane potential and oxidants. *J Neurosci Methods* 104:165–176. doi:10.1016/S0165-0270(00) 00340-X
29. Soignet SL, Maslak P, Wang ZG et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. *N Engl J Med* 339:1341–1348. doi:10.1056/NEJM199811053391901
30. Shen ZX, Chen GQ, Ni JH et al (1997) Use of arsenic trioxide (As_2O_3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. *Blood* 89:3354–3360
31. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG (1995) Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. *Oncol Res* 7:83–95
32. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. *Cancer Res* 55:1339–1346
33. Zhang P, Wang SY, Hu XH (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. *Chin J Hematol* 17:58–62
34. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A (2002) Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. *Am J Hematol* 70:292–299. doi:10.1002/ajh.10138
35. Niu C, Yan H, Yu T et al (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. *Blood* 94:3315–3324
36. Spencer A, Firkin F (1999) Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience. *Aust N Z J Med* 29:385–386 letter
37. Warrell RP Jr, Soignet SL, Maslak P et al (1998) Initial Western study of arsenic trioxide in acute promyelocytic leukemia. *J Clin Oncol* 17(Suppl.):19
38. Ohnishi K, Yoshida H, Shigeno K et al (2002) Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. *Leukemia* 16:617–622. doi:10.1038/sj.leu.2402426
39. Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z (1999) Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-*trans*-retinoic acid, chemotherapy, and As_2O_3 : an experience of 120 patients at a single institution. *Int J Hematol* 70:248–260
40. Hu J, Shen Z, Sun H et al (2000) Long-term survey of outcome in acute promyelocytic leukemia. *Chin Med J (Engl)* 113:107–110. doi:10.3901/JME.2000.08.107
41. Soignet SL, Frankel SR, Douer D et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. *J Clin Oncol* 19:3852–3860
42. Ni J, Chen G, Shen Z et al (1998) Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. *Chin Med J (Engl)* 111:1107–1110
43. Soignet SL (2001) Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. *Oncologist* 6:11–16. doi:10.1634/theoncologist.6-suppl_2-11
44. Jiong H, Zhixiang S, Wen W, Xiusong L, Guanlin S, Zhenyi W (2000) Long-term survey of outcome in acute promyelocytic leukemia. *Chin Med J (Engl)* 113:107–110
45. Camacho LH, Soignet SL, Chaneil S et al (2000) Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. *J Clin Oncol* 18:2620–2625
46. Hussein MA, Elson P, Reed J et al (2003) Arsenic trioxide (Trisenox™), ascorbic acid (AA), and dexamethasone (Dex) pulses-TAD for relapsed refractory progressive multiple myeloma patients. *Hematol J* 4:S257
47. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I et al (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. *Clin Cancer Res* 8:3658–3668
48. Munshi NC, Desikan R, Zangari M (1999) Marked anti-tumor effect of arsenic trioxide (As_2O_3) in high risk refractory multiple myeloma. *Blood* 94:123a
49. Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC (2002) Novel biologically based therapies for multiple myeloma. *Int J Hematol* 76:340–341
50. Munshi NC, Tricot G, Desikan R et al (2002) Clinical activity of arsenic trioxide for the treatment of multiple myeloma. *Leukemia* 16:1835–1837. doi:10.1038/sj.leu.2402599
51. Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G (2000) Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? *Haematologica* 85:1002–1003
52. Cheson BD, Zwiebel JA, Dancy J, Murgo A (2000) Novel therapeutic agents for the treatment of myelodysplastic syndromes. *Semin Oncol* 27:560–577
53. List A, Beran M, DiPersio J et al (2003) Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. *Leukemia* 17:1499–1507. doi:10.1038/sj.leu.2403021
54. Vuky J, Yu R, Schwartz L, Motzer RJ (2002) Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. *Invest New Drugs* 20:327–330. doi:10.1023/A:1016270206374

55. Lecureur V, Lagadic-Gossmann D, Fardel O (2002) Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells. *Int J Oncol* 20:1071–1076
56. Mann KK, Davison K, Colombo M et al (2006) Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling. *Toxicol Lett* 160:158–170. doi:[10.1016/j.toxlet.2005.06.017](https://doi.org/10.1016/j.toxlet.2005.06.017)
57. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI (2002) Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. *Clin Cancer Res* 8:566–572
58. Chouchane S, Snow ET (2001) In vitro effect of arsenical compounds on glutathione-related enzymes. *Chem Res Toxicol* 14:517–522. doi:[10.1021/tx000123x](https://doi.org/10.1021/tx000123x)
59. Larochette N, Decaudin D, Jacotot E et al (1999) Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. *Exp Cell Res* 249:413–421. doi:[10.1006/excr.1999.4519](https://doi.org/10.1006/excr.1999.4519)
60. Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. *J Biol Chem* 257:13704–13712
61. Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. *Blood* 93:268–277
62. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. *Blood* 94:2102–2111
63. Chattopadhyay S, Ghosh S, Debnath J, Ghosh D (2001) Protection of sodium arsenite-induced ovarian toxicity by coadministration of L-ascorbate (vitamin C) in mature Wistar strain rat. *Arch Environ Contam Toxicol* 41:83–89. doi:[10.1007/s002440010223](https://doi.org/10.1007/s002440010223)
64. Block G, Henson DE, Levine M (1991) Vitamin C: a new look. *Ann Intern Med* 114:909–910
65. Bijur GN, Ariza ME, Hitchcock CL, Williams MV (1997) Antimutagenic and promutagenic activity of ascorbic acid during oxidative stress. *Environ Mol Mutagen* 30:339–345. doi:[10.1002/\(SICI\)1098-2280\(1997\)30:3<339::AID-EM13>3.0.CO;2-E](https://doi.org/10.1002/(SICI)1098-2280(1997)30:3<339::AID-EM13>3.0.CO;2-E)
66. Sakagami H, Satoh K (1997) Modulating factors of radical intensity and cytotoxic activity of ascorbate. *Anticancer Res* 17:3513–3520 Review
67. Subbarayan PR, Lima M, Ardan B (2007) Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. *Acta Oncol* 46:557–561. doi:[10.1080/02841860601042456](https://doi.org/10.1080/02841860601042456)
68. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS (2007) A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. *Clin Cancer Res* 13:1762–1768. doi:[10.1158/1078-0432.CCR-06-1812](https://doi.org/10.1158/1078-0432.CCR-06-1812)
69. Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P (2006) Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. *Haematologica* 91:1722–1723